Lazabemide
Lazabemide is a monoamine oxidase inhibitor (MAOI) that was primarily developed for the treatment of Parkinson's disease. It is a selective and reversible inhibitor of monoamine oxidase B (MAO-B), which means it temporarily deactivates the MAO-B enzyme to increase the levels of beneficial neurotransmitters in the brain.
Pharmacology[edit]
Lazabemide works by selectively and reversibly inhibiting the monoamine oxidase B (MAO-B) enzyme. This enzyme is responsible for the breakdown of dopamine, a neurotransmitter that plays a crucial role in the regulation of movement and mood. By inhibiting MAO-B, Lazabemide increases the availability of dopamine in the brain, which can help alleviate the symptoms of Parkinson's disease.
Clinical Use[edit]
Lazabemide was primarily developed for the treatment of Parkinson's disease. It has been studied in several clinical trials and has shown promise in reducing the motor symptoms associated with the disease. However, it has not been widely adopted in clinical practice due to concerns about its safety and efficacy compared to other available treatments.
Side Effects[edit]
Like all medications, Lazabemide can cause side effects. The most common side effects include nausea, dry mouth, and insomnia. In rare cases, it can cause more serious side effects such as hallucinations, severe headache, and chest pain. It is important for patients to discuss any side effects they experience with their healthcare provider.
See Also[edit]
| Parkinson's disease and related topics | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
This Parkinson's disease-related article is a stub. You can help WikiMD by expanding it.
|
| Monoamine oxidase inhibitors | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
This Monoamine oxidase inhibitor related article is a stub.
|
